MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline ...

The European Union's drug regulator has recommended approval of Moderna's updated formulation of COVID-19 shot Spikevax, the ...

Moderna has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

The COVID pandemic likely began when the virus jumped from animals to humans, and didn’t start in a lab. But false narratives ...

Vinay Prasad overruled other reviewers for a third time in recent months in clearing only narrow use of Moderna's vaccine in ...

If you're confident that its current trials will prove successful, then this is one to buy and sit on. One word of caution ...

Moderna announced Monday that its COVID-19 vaccine booster increases antibody levels against the omicron variant within a month of getting the shot. In a lab study, the company gave 20 fully ...

Moderna’s Covid vaccine for children has been given full FDA approval, making it the first such shot for kids in the U.S. that will no longer be administered under an emergency use authorization.

The primary efficacy was to demonstrate the vaccine efficacy against COVID-19 starting 14 days after mNEXSPIKE compared with Spikevax, Moderna's updated COVID-19 vaccine approved on Sept. 6, 2024.

WASHINGTON — The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement for the company’s existing shot, but a second option.

In preclinical studies, Moderna has observed that its seasonal flu and COVID-19 booster vaccines can be combined into one dose that produces an immune response to both viruses.